Oxford Biomedica

Overview

Oxford Biomedica (OXB) is a global, full-service, quality and innovation-led viral vector CDMO specializing in the development, scale-up, and GMP-compliant manufacture of cell and gene therapy products. Founded in 1995 as a spin-out from the University of Oxford, OXB has evolved into a leading contract development and manufacturing organization with over 30 years of experience in viral vector technology.

Core Capabilities

Viral Vector Platforms:

• Lentivirus: 30 years of pioneering experience; scalable production from 50L to 1000L across harmonized global processes
• AAV: Proprietary inAAVate™ platform delivering GMP AAV in as little as 7 months; achieves titres of 1.5E+17vgs from 500L bioreactors with 90% full capsids
• Adenovirus: Proven large-scale manufacturing (100+ million doses of Oxford–AstraZeneca COVID-19 vaccine); flexible end-to-end CDMO model
• Other vectors: MVA (Modified Vaccinia Ankara) and other poxvirus-based vectors for immuno-oncology and infectious disease vaccines

Service Models:

• Platform projects for preclinical/early-clinical clients seeking accelerated GMP timelines with proven processes
• Custom solutions offering flexibility for preclinical/early-clinical development
• Technology transfer for Phase I, II, and III programs requiring scale-up and long-term manufacturing

Regulatory & Infrastructure:

• End-to-end regulatory support from preclinical development through commercial launch
• Multiple IND and MAA submissions supported
• FDA Drug Master File (DMF) maintained
• GMP facilities in UK, Europe (France), and USA
• State-of-the-art infrastructure aligned to global regulatory standards

Market Position

Recognized by Fortune as one of Europe's Most Innovative Companies in 2025. Trusted partner to leading biopharma companies, biotech firms, and start-ups worldwide.